From Yahoo Finance: 2025-05-11 17:25:00

President Trump’s executive order on healthcare aims to revamp Medicare’s ability to negotiate drug prices. Drug makers work to delay price negotiation eligibility for small-molecule drugs by four years. Trump’s order also targets cutting healthcare costs and may lead to sector-specific tariffs. Medicare’s negotiating powers have been a point of contention.
The Biden administration negotiated price cuts of up to 79% for expensive drugs, while the Trump administration aims to negotiate prices for 15 medications. iRhythm Technologies, Inc. (NASDAQ:IRTC) is a digital healthcare company that has seen significant revenue growth and potential. They are also progressing on regulatory fronts and rank 4th on the best performing healthcare stocks list.
Analysts at Canaccord Genuity maintain a Buy rating on iRhythm Technologies, Inc. (NASDAQ:IRTC) with a $139.00 price target. The company’s strong performance is attributed to the success of its Zio AT product. iRhythm Technologies, Inc. (NASDAQ:IRTC) plans to submit the Zio Monitor in Q3 and complete compliance efforts by the end of 2025.
Overall, iRhythm Technologies, Inc. (NASDAQ:IRTC) ranks 4th on the list of best performing healthcare stocks. While it shows promise, some AI stocks may offer higher returns within a shorter time frame. Investors seeking an AI stock with potential gains may find options in the market.

Read more: Why iRhythm Technologies (IRTC) Is Among the Best Performing Healthcare Stocks to Buy Now